Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan

Gastric Cancer

Volumn 10, Issue 1, 2007, Pages 52-57

  Kobayashi, Michiya ^a   Oba, Koji ^b   Sakamoto, Junichi ^c   Kondo, Ken ^d   Nagata, Naoki ^e   Okabayashi, Takehiro ^a   Namikawa, Tsutomu ^a   Hanazaki, Kazuhiro ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^e UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Advanced gastric cancer; Chemotherapy; Gastric cancer; Paclitaxel; Pharmacokinetic study

Indexed keywords

CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; FLUOROURACIL; PACLITAXEL; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG TOLERABILITY; FEMALE; HUMAN; JAPAN; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STOMACH CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; STOMACH NEOPLASMS;

EID: 33847631750     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-006-0411-6     Document Type: Article

References (25)

1. EK Rowinsky RC Donehower 1995 Paclitaxel (Taxol) N Engl J Med 332 1004 14
2. Y-F Chang LL Li C-W Wu W-Y Liu F-K P'eng C-W Chi 1996 Paclitaxel-induced apoptosis in human gastric carcinoma cell lines Cancer 77 14 8
3. HY Kim SW Shin BS Kim JH Kim JG Kim YJ Mok 1999 Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma Cancer 85 295 301
4. AM Murad A Petroianu RC Guimaraes BC Aragao LOM Cabral AO Scalabrini-Neto 1999 Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer. A novel, safe, and effective regimen Am J Clin Oncol 22 580 6
5. JJ Lokich H Sonneborn NR Anderson MM Bern FV Coco E Dow P Oliynyk 1999 Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas Cancer 85 2347 51
6. C Kollmannsberger D Quietzsch C Haag T Lingenfelser M Schroeder JT Hartmann 2000 A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer Br J Cancer 83 458 62
7. AA Garcia CG Leichman HJ Lenz J Baranda R Lujan Y Casagrande L Leichman 2001 Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenocarcinoma of the stomach Jpn J Clin Oncol 31 275 8
8. Y Yamada K Shirao A Ohtsu N Boku I Hyodo Y Miyata T Taguchi 2001 Phase II trial of paclitaxel by 3-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions Ann Oncol 12 1133 7
9. H Matsuoka K Yano Y Saito H Tomoda 1995 Cytotoxicity of paclitaxel in comparison with other anticancer agents against neoplastic cells obtained from clinical gastrointestinal carcinoma tissue Anticancer Res 15 2001 6
10. D Fennelly C Aghajanian F Shapiro C O'Flaherty M [tmp] McKenzie C O'Connor 1997 Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer J Clin Oncol 15 187 92
11. U Klaassen H Wilke D Stumberg W Eberhardt M Korn S Seeber 1996 Phase I study with a weekly 1-h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer Eur J Cancer 32A 547 9
12. Y Segawa K Watanabe S Hiraki K Tominaga I Hayashi M Harada 2000 Phase I study of docetaxel and cisplatin for patients with previously untreated metastatic non-small-cell lung cancer: a Japanese cooperative study Int J Clin Oncol 5 308 15
13. Y Kano M Akutsu S Tsunoda J Matsui K Suzuki T Ikeda 1996 Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro Br J Cancer 74 704 10
14. R Shimon EL Karn 1990 Selecting drug combinations based on total equivalent dose (dose intensity) J Natl Cancer Inst 82 1469 76
15. P Pronzato G Bertelli A Vigani F Vaira 1996 A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin, and cyclophosphamide (PEC) in advanced ovarian cancer Br J Cancer 73 1425 7
16. National Cancer Institute 1993 NCI common toxicity criteria, version 1 Investigators handbook: a manual of participants in clinical trials of investigational agents, sponsored by the Division of Cancer Treatment, National Cancer Institute U.S. Department of Health and Human Services, Public Health Service, National Institute of Health Bethesda, MD
17. PH Wiernik EL Schwartz A Einzig JJ Strauman RB Lipton JP Cutcher 1987 Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma J Clin Oncol 5 1232 9
18. U Vanhoefer P Rougier H Wilke MP Ducreux AJ Lacave E Van Cutsem 2000 Final result of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group J Clin Oncol 18 2648 57
19. A Ohtsu Y Shimada S Yoshida H Saito S Seki K Morise M Kurihara 1994 Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG) Eur J Cancer 30A 2091 3
20. Y Shimada K Shirao A Ohtsu I Hyodo H Saito N Yamamichi 1999 Phase III study of UFT + MMC versus 5-FU + CDDP versus 5-FU alone in patients with advanced gastric cancer. JCOG study 9205 (abstract) Proc ASCO 18 272
21. K Yamaguchi M Tada N Horikoshi T Otani H Takiuchi S Saitoh 2002 Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer Gastric Cancer 5 90 5
22. P Rosenberg H Anderson K Boman M Ridderheim B Sorbe U Puistola G Horvath 1999 A randomized multicenter study of single agent paclitaxel given weekly versus every 3 weeks to patients with ovarian cancer previously treated with platinum therapy (abstract) Proc ASCO 18 368a
23. L Norton 2001 Theoretical concepts and the emerging role of taxanes in adjuvant therapy Oncologist 6 Suppl 3 30 5
24. MJ Glantz H Choy W Akerley CM Kearns MJ Egorin CH Rhodes BF Cole 1996 Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response Semin Oncol 23 6 Suppl 16 128 35
25. MM Oken RH Creech DC Tormey J Horton TE Davis ET [tmp] McFadden 1982 Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 6 649 55